Sight Diagnostics
Active
Blood Diagnostics Healthcare
Computer Vision Machine Learning

Business Overview

DESCRIPTION

Sight Diagnostics uses advanced computer-vision and machine-learning technology in the realm of blood diagnostics. Sight’s initial product, the Parasight platform, is a device for malaria diagnosis and offers high accuracy and ease of use. The company is applying its technology to the complete blood count (CBC) market, developing a point-of-care CBC platform which will provide a five-point differential blood count for use in doctors’ offices and emergency medical centers. Beyond malaria and CBC, Sight’s computer-vision technology has the potential to unlock advanced diagnostic approaches to numerous additional diseases and provide more accurate and cheaper testing for the patient.

FOUNDED
January 2011
EMPLOYEES
84
BUSINESS MODEL
B2B
OFFERING TYPE
Software
FUNDING STAGE
Series D
TOTAL FUNDING
$124 Million
SECTORS
Blood Diagnostics Healthcare

Funding Rounds

Date Announced

Funding Round

Amount Raised

Investors

July 2020
Series D
$71 M
April 2014
Series A
$6 M
August 2011
Seed
$3.2 M

AI Technology Stack

AI EMPLOYEES
15
AI TYPES
Computer Vision Machine Learning